Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5W23

Crystal Structure of RSV F in complex with 5C4 Fab

Summary for 5W23
Entry DOI10.2210/pdb5w23/pdb
DescriptorFusion glycoprotein F0, 5C4 Fab heavy chain, 5C4 Fab light chain, ... (4 entities in total)
Functional Keywordsrsv, complex, fab, antibody, neutralizing antibody, viral protein-immune system complex, viral protein/immune system
Biological sourceHuman respiratory syncytial virus A
More
Cellular locationVirion membrane; Single-pass type I membrane protein: P03420
Total number of polymer chains9
Total formula weight350086.04
Authors
Battles, M.B.,McLellan, J.S. (deposition date: 2017-06-05, release date: 2017-12-06, Last modification date: 2024-11-13)
Primary citationTian, D.,Battles, M.B.,Moin, S.M.,Chen, M.,Modjarrad, K.,Kumar, A.,Kanekiyo, M.,Graepel, K.W.,Taher, N.M.,Hotard, A.L.,Moore, M.L.,Zhao, M.,Zheng, Z.Z.,Xia, N.S.,McLellan, J.S.,Graham, B.S.
Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.
Nat Commun, 8:1877-1877, 2017
Cited by
PubMed Abstract: A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. Here we show that unlike D25, 5C4 preferentially neutralizes subtype A viruses. The crystal structure of 5C4 bound to the RSV fusion (F) protein reveals that the overall binding mode of 5C4 is similar to that of D25, but their angles of approach are substantially different. Mutagenesis and virological studies demonstrate that RSV F residue 201 is largely responsible for the subtype specificity of 5C4. These results improve our understanding of subtype-specific immunity and the neutralization breadth requirements of next-generation antibodies, and thereby contribute to the design of broadly protective RSV vaccines.
PubMed: 29187732
DOI: 10.1038/s41467-017-01858-w
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.4 Å)
Structure validation

236371

PDB entries from 2025-05-21

PDB statisticsPDBj update infoContact PDBjnumon